Conditioning Patients to Increase DC-vaccine Potency

对患者进行调理以提高 DC 疫苗的效力

基本信息

  • 批准号:
    7122673
  • 负责人:
  • 金额:
    $ 10.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-03-01 至 2009-05-31
  • 项目状态:
    已结题

项目摘要

Vaccination of HLA-A*201 patients with metastatic melanoma with dendritic cells (DCs) derived from CD34+ hematopoietic cell progenitor cells (CD34+HPCs) loaded with melanoma peptide antigens, KLH and flu peptide resulted in the induction of CD8+ T cell immunity to melanoma peptides and some clinical benefit. Immunity was measured by the production of interferon-gamma in the presence of melanoma peptides and control antigens by CD8+ T cells obtained from blood. T cell immunity correlated with early clinical outcome and survival. Patients who progressed early had either no T cell immunity or transient T cell immunity to DC vaccination. There may be several reasons for the absence of DC-induced CD8+ T cell immunity in these patients including: the inability of DCs to prime T cells against tumor antigens, the presence of tumor specific tolerance induced by host suppressor lymphocytes, and an insufficient anti-melanoma T cell repertoire. AIM 1 will determine whether pre-treatment of patients with stage IV melanoma with CPA improves the immune and clinical response after DC vaccination. We will carry out a phase l/ll randomized clinical trial in patients with stage IV melanoma who will receive either placebo or CPA (500mg/m2) followed by vaccination with CD34-DCs pulsed with melanoma peptides and KLH. As a control, a separate aliquot of DCs will be pulsed with HIV peptides as neoantigens that will be mixed with the peptide-loaded DCs and administered at the same time. The primary outcome is the induction of melanoma-specific CD8+T cell immunity. The secondary outcome is the rate of objective clinical responses. Tertiary outcomes are: reduction of regulatory/suppressor CD4+T cells (AIM 2) and priming of HIV-specific CD8+T cells (AIM 3).
CD34+来源树突状细胞(dc)转移性黑色素瘤患者的HLA-A*201疫苗接种

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSEPH Wayne FAY其他文献

JOSEPH Wayne FAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSEPH Wayne FAY', 18)}}的其他基金

Clinical Samples
临床样本
  • 批准号:
    8307079
  • 财政年份:
    2011
  • 资助金额:
    $ 10.09万
  • 项目类别:
Core--Clinical
核心--临床
  • 批准号:
    7122678
  • 财政年份:
    2006
  • 资助金额:
    $ 10.09万
  • 项目类别:
Conditioning Patients to Increase DC-vaccine Potency
对患者进行调理以提高 DC 疫苗的效力
  • 批准号:
    7631317
  • 财政年份:
    2000
  • 资助金额:
    $ 10.09万
  • 项目类别:
Core--Clinical
核心--临床
  • 批准号:
    7631320
  • 财政年份:
    2000
  • 资助金额:
    $ 10.09万
  • 项目类别:
Clinical Samples
临床样本
  • 批准号:
    8376053
  • 财政年份:
  • 资助金额:
    $ 10.09万
  • 项目类别:
Clinical Samples
临床样本
  • 批准号:
    8691697
  • 财政年份:
  • 资助金额:
    $ 10.09万
  • 项目类别:
Conditioning Patients to Increase DC-vaccine Potency
对患者进行调理以提高 DC 疫苗的效力
  • 批准号:
    7460927
  • 财政年份:
  • 资助金额:
    $ 10.09万
  • 项目类别:
Clinical Samples
临床样本
  • 批准号:
    8501333
  • 财政年份:
  • 资助金额:
    $ 10.09万
  • 项目类别:
Core--Clinical
核心--临床
  • 批准号:
    7460930
  • 财政年份:
  • 资助金额:
    $ 10.09万
  • 项目类别:

相似海外基金

Chemoresistance and Stem Cell Selection
化疗耐药性和干细胞选择
  • 批准号:
    7049120
  • 财政年份:
    2006
  • 资助金额:
    $ 10.09万
  • 项目类别:
Total Synthesis of Bielschowskysin
Bielschowskysin 的全合成
  • 批准号:
    6999898
  • 财政年份:
    2006
  • 资助金额:
    $ 10.09万
  • 项目类别:
High throughput screening for inhibitors of Akt plasma m
高通量筛选 Akt 血浆抑制剂
  • 批准号:
    7168662
  • 财政年份:
    2006
  • 资助金额:
    $ 10.09万
  • 项目类别:
A High Throughput Screen for Telomerase Assembly (RMI)
端粒酶组装 (RMI) 的高通量筛选
  • 批准号:
    7021596
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
Genetic Screening:Oncogene RAS-Based Inhibi*(RMI)
基因筛查:Oncogene RAS-Based Inhibi*(RMI)
  • 批准号:
    7058055
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
Preoperative chemotherapy for breast cancer
乳腺癌术前化疗
  • 批准号:
    6863195
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
preoprative chemotherapy for breast cancer
乳腺癌术前化疗
  • 批准号:
    7054103
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
An IL-2 Receptor Targeted Toxin with Reduced VLS
具有减少 VLS 的 IL-2 受体靶向毒素
  • 批准号:
    6883320
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
Microfluidic Reconstituted Mammary Tissue System
微流控重建乳腺组织系统
  • 批准号:
    6883038
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
Molecular screens for pVHL-associated isopeptidase VDU1
pVHL 相关肽酶 VDU1 的分子筛选
  • 批准号:
    6941091
  • 财政年份:
    2005
  • 资助金额:
    $ 10.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了